Clofarabine Commandeers the RNR-α-ZRANB3 Nuclear Signaling Axis

Highlights

• ZRANB3 is required for DNA synthesis in various cell types

• Drugs promoting nuclear translocation of enzyme RNR-α inhibit this ZRANB3 function

• ZRANB3 is an example of non-oncogene addiction during H-ras^G12V-driven transformation

• Upregulating the levels of nuclear RNR-α offers a means to target oncogenesis

Summary

Ribonucleotide reductase (RNR) is an essential enzyme in DNA biogenesis and a target of several chemotherapeutics. Here, we investigate how anti-leukemic drugs (e.g., clofarabine [ClF]) that target one of the two subunits of RNR, RNR-α, affect non-canonical RNR-α functions. We discovered that these clinically approved RNR-inhibiting dATP-analogs inhibit growth by also targeting ZRANB3—a recently identified DNA synthesis promoter and nuclear-localized interactor of RNR-α. Remarkably, in early time points following drug treatment, ZRANB3 targeting accounted for most of the drug-induced DNA synthesis suppression and multiple cell types featuring ZRANB3 knockout/knockdown were resistant to these drugs. In addition, ZRANB3 plays a major role in regulating tumor invasion and H-ras^G12V-promoted transformation in a manner dependent on the recently discovered interactome of RNR-α involving select cytosolic-/nuclear-localized protein players. The H-ras^G12V-promoted transformation—which we show requires ZRANB3-supported DNA synthesis—was efficiently suppressed by ClF. Such overlooked mechanisms of action of approved drugs and a previously unappreciated example of non-oncogene addiction, which is suppressed by RNR-α, may advance cancer interventions.